See more : discoverIE Group plc (DSCV.L) Income Statement Analysis – Financial Results
Complete financial analysis of ReWalk Robotics Ltd. (LFWD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ReWalk Robotics Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- Zegona Communications plc (ZEG.L) Income Statement Analysis – Financial Results
- Konfoong Materials International Co., Ltd (300666.SZ) Income Statement Analysis – Financial Results
- TIL Ltd (TIL-RE.NS) Income Statement Analysis – Financial Results
- Niraj Cement Structurals Limited (NIRAJ.NS) Income Statement Analysis – Financial Results
- InfoSearch Media, Inc. (ISHM) Income Statement Analysis – Financial Results
ReWalk Robotics Ltd. (LFWD)
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.85M | 5.51M | 5.97M | 4.39M | 4.87M | 6.55M | 7.75M | 5.87M |
| Cost of Revenue | 9.40M | 3.61M | 3.06M | 2.20M | 2.15M | 3.72M | 4.65M | 5.13M |
| Gross Profit | 4.45M | 1.91M | 2.90M | 2.19M | 2.73M | 2.83M | 3.10M | 736.00K |
| Gross Profit Ratio | 32.14% | 34.57% | 48.66% | 49.83% | 55.94% | 43.16% | 40.00% | 12.54% |
| Research & Development | 4.15M | 4.03M | 2.94M | 3.46M | 5.35M | 7.35M | 6.04M | 9.03M |
| General & Administrative | 10.00M | 7.13M | 5.63M | 4.98M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 13.92M | 9.84M | 6.99M | 5.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.92M | 16.98M | 12.62M | 10.73M | 11.43M | 14.69M | 19.05M | 22.15M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 28.07M | 21.01M | 15.56M | 14.19M | 16.77M | 22.04M | 25.09M | 31.18M |
| Cost & Expenses | 37.47M | 24.61M | 18.62M | 16.40M | 18.92M | 25.76M | 29.75M | 36.31M |
| Interest Income | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 |
| Interest Expense | 20.00K | 22.00K | 25.00K | 907.00K | 1.53M | 2.42M | 2.48M | 2.01M |
| Depreciation & Amortization | 1.85M | 202.00K | 266.00K | 285.00K | 321.00K | 463.00K | 642.00K | 696.00K |
| EBITDA | -21.77M | -18.90M | -12.39M | -11.73M | -13.72M | -18.79M | -21.48M | -29.79M |
| EBITDA Ratio | -157.10% | -343.35% | -208.30% | -267.29% | -281.70% | -286.49% | -275.38% | -506.82% |
| Operating Income | -23.61M | -19.10M | -12.66M | -12.00M | -14.05M | -19.21M | -21.99M | -30.44M |
| Operating Income Ratio | -170.43% | -346.62% | -212.12% | -273.25% | -288.28% | -293.57% | -283.66% | -518.67% |
| Total Other Income/Expenses | 1.47M | 0.00 | 13.00K | -921.00K | -1.50M | -2.47M | -2.61M | -2.06M |
| Income Before Tax | -22.15M | -19.10M | -12.64M | -12.93M | -15.54M | -21.68M | -24.60M | -32.50M |
| Income Before Tax Ratio | -159.85% | -346.62% | -211.90% | -294.22% | -318.98% | -331.25% | -317.27% | -553.76% |
| Income Tax Expense | -12.00K | 467.00K | 94.00K | 51.00K | 7.00K | -5.00K | 119.00K | 3.00K |
| Net Income | -22.13M | -19.57M | -12.74M | -12.98M | -15.55M | -21.68M | -24.72M | -32.50M |
| Net Income Ratio | -159.76% | -355.09% | -213.48% | -295.38% | -319.13% | -331.17% | -318.81% | -553.81% |
| EPS | -2.59 | -2.20 | -1.86 | -5.74 | -18.90 | -103.04 | -213.98 | -431.63 |
| EPS Diluted | -2.59 | -2.20 | -1.86 | -5.74 | -18.90 | -103.04 | -213.98 | -431.63 |
| Weighted Avg Shares Out | 8.53M | 8.91M | 6.85M | 2.25M | 823.33K | 210.36K | 115.51K | 75.30K |
| Weighted Avg Shares Out (Dil) | 8.53M | 8.91M | 6.85M | 2.25M | 823.33K | 210.36K | 115.51K | 75.30K |
ReWalk (LFWD) Upgraded to Strong Buy: Here's What You Should Know
3 Stocks Backed by High Efficiency to Strengthen Your Portfolio
Lifeward to Report First Quarter Financial Results on May 15, 2024
Earnings Preview: ReWalk Robotics (LFWD) Q1 Earnings Expected to Decline
Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?
Bears are Losing Control Over ReWalk (LFWD), Here's Why It's a 'Buy' Now
Lifeward Announces the Appointment of Mike Swinford to its Board of Directors
Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton
Unleashing the Underdogs: 3 Hidden Gems Set to Conquer the Market
Source: https://incomestatements.info
Category: Stock Reports